# OnCo record paper-lenz-cms-calgb-swog-80405-jco-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-lenz-cms-calgb-swog-80405-jco-2019" ;
  schema:name "Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405"@en ;
  schema:description "In the one randomised trial where the four gene-activity subtypes were measured, they predicted not only how long people lived but which biological drug worked better: the immune subtype did better with bevacizumab and the canonical subtype with cetuximab."@en ;
  schema:url <https://onco.cc/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.18.02258>, <https://pubmed.ncbi.nlm.nih.gov/31042420/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.18.02258> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Lenz HJ, Ou FS, Venook AP, et al." ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/rna-seq/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/cetuximab/> ;
  onco:terms <https://onco.cc/terms/cms-subtypes/> ;
  onco:people <https://onco.cc/people/heinz-josef-lenz/>, <https://onco.cc/people/alan-venook/> ;
  onco:journals <https://onco.cc/journals/jco/> .